Vega Therapeutics, Inc.: Vega Therapeutics Initiates Clinical Trial Program for VGA039, a First-in-Class Antibody Therapy for von Willebrand Disease

Phase 1 clinical trial advances with first subject dosed in the E.U. and IND accepted in the U.S. Vega Therapeutics, Inc., a clinical stage biotechnology company developing novel therapies for rare

Related Keywords

Willebrand ,Nordrhein Westfalen ,Germany ,Ayesha Zia ,Barbara Yates ,Gary Patou ,Yates Network ,Hemostasis Thrombosis Program ,Linkedin ,Vega Therapeutics Inc ,University Of Texas Southwestern Medical Center ,Drug Administration ,Investigational New Drug Application ,Clinical Trial Application ,Chief Medical Officer ,Texas Southwestern Medical ,Vega ,Herapeutics ,Nitiates ,Linical ,Trial ,Program ,Ga039 ,First ,Glass ,Ntibody ,Therapy ,Disease ,